Naoshad Muhammad

Naoshad Muhammad

Auto-generated profile, based on publicly available information

Naoshad Muhammad

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
NMNaoshad Muhammad
Naoshad Muhammad
SBSourav Bhattacharya
Sourav Bhattacharya
RSRobert Steele
Robert Steele
Ratna B. RayRatna B. Ray
Ratna B. Ray
Breast cancer is a major public health problem worldwide in women and existing treatments are not adequately effective for this deadly disease. microRNAs (miRNAs) regulate the expression of many target genes and play pivotal roles in the development, as well as in the suppression of many cancers including breast cancer. We previously observed that miR-203 was highly upregulated in breast cancer tissues and in ER-positive breast cancer cell lines. In our present study, we observed that anti-miR-203 suppresses breast cancer cell proliferation in vitro. Orthotopic implantation of miR-203 depleted MCF-7 cells into nude mice displays smaller tumor growth as compared to control MCF-7 cells. Furthermore, miR-203 expression is significantly higher in ER-positive breast cancer patients as compared to ER-negative patients. We identified suppressor of cytokine signaling 3 (SOCS3) as a direct target of miR-203. Here we observed that miR-203 expression is inversely correlated with SOCS3 expression in ER-positive breast cancer samples. Additionally, we found that anti-miR-203 suppressed the expression of pStat3, pERK and c-Myc in MCF-7 and ZR-75-1 cells. We also demonstrated that anti-miR-203 decreased mammospheres formation and expression of stem cell markers in MCF-7 and ZR-75-1 cells. Taken together, our data suggest that anti-miR-203 has potential as a novel therapeutic strategy in ER-positive breast cancer treatment.

14 June 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NMNaoshad Muhammad
Naoshad Muhammad
SBSourav Bhattacharya
Sourav Bhattacharya
RSRobert Steele
Robert Steele
NPNancy Phillips
Nancy Phillips
Ratna B. RayRatna B. Ray
Ratna B. Ray
Purpose: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Although improvements in surgical techniques, chemotherapy and radiation delivery, and supportive care have improved quality of life for patients with HNSCC, regional and distant recurrence remain common. Recent evidence suggests that cancer stem-like cells (CSC) play a significant role in recurrence and chemoresistance. We previously observed that c-Fos was highly upregulated in the HNSCC sphere–forming cells. Consequences of c-Fos upregulation for the biology of HNSCC-CSCs are poorly understood. In this study, we investigated the role of c-Fos in renewal of stemness of HNSCC and tumor growth. Experimental Design and Results: We generated stable HNSCC cell lines ectopically expressing the c-Fos gene. Exogenous expression of c-Fos in nontumorigenic MDA1386Tu cells makes these cells tumorigenic in nude mice. Furthermore, subcutaneous transplantation of c-Fos–overexpressing Cal27 cells (tumorigenic) into immunocompromised mice enhanced tumor growth as compared with parental cells. Mechanistic investigations demonstrated that c-Fos overexpression enhanced the epithelial–mesenchymal transition (EMT) state and expression of CSC markers (Nanog, c-Myc, Sox2, and Notch1). Ectopic expression of c-Fos in HNSCC cells also displays increased sphere formation. We further observed that overexpression of c-Fos increased the expression of pERK and cyclin D1 in HNSCC cells. Conclusions: Together, our results strongly suggest a novel role of c-Fos as a regulator of EMT and cancer stem cell reprogramming in HNSCC cells, which may hold potential as a CSC-directed therapeutic approach to improve HNSCC treatment. Clin Cancer Res; 23(12); 3120–8. ©2016 AACR.

3 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
NMNaoshad Muhammad
Naoshad Muhammad
RSRobert Steele
Robert Steele
TIT. Scott Isbell
T. Scott Isbell
NPNancy Philips
Nancy Philips
Ratna B. RayRatna B. Ray
Ratna B. Ray
Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death

1 June 2017 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
SBSourav Bhattacharya
Sourav Bhattacharya
NMNaoshad Muhammad
Naoshad Muhammad
RSRobert Steele
Robert Steele
JKJacki Kornbluth
Jacki Kornbluth
Ratna B. RayRatna B. Ray
Ratna B. Ray
Natural killer (NK) cells are one of the major components of innate immunity, with the ability to mediate antitumor activity. Understanding the role of NK-cell–mediated tumor killing in controlling of solid tumor growth is still in the developmental stage. We have shown recently that bitter melon extract (BME) modulates the regulatory T cell (Treg) population in head and neck squamous cell carcinoma (HNSCC). However, the role of BME in NK-cell modulation against HNSCC remains unknown. In this study, we investigated whether BME can enhance the NK-cell killing activity against HNSCC cells. Our results indicated that treatment of human NK-cell line (NK3.3) with BME enhances ability to kill HNSCC cells. BME increases granzyme B accumulation and translocation/accumulation of CD107a/LAMP1 in NK3.3 cells exposed to BME. Furthermore, an increase in cell surface expression of CD16 and NKp30 in BME-treated NK3.3 cells was observed when cocultured with HNSCC cells. Collectively, our results demonstrated for the first time that BME augments NK-cell–mediated HNSCC killing activity, implicating an immunomodulatory role of BME. Cancer Prev Res; 10(6); 337–44. ©2017 AACR.

21 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
SBSourav Bhattacharya
Sourav Bhattacharya
NMNaoshad Muhammad
Naoshad Muhammad
RSRobert Steele
Robert Steele
GPGuangyong Peng
Guangyong Peng
Ratna B. RayRatna B. Ray
Ratna B. Ray
Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth

5 July 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MSMohd Suhail
Mohd Suhail
MTMohammad Tarique
Mohammad Tarique
NMNaoshad Muhammad
Naoshad Muhammad
HNHuma Naz
Huma Naz
AHAbdul Hafeez
Abdul Hafeez
MRMohd Rehan
Mohd Rehan
Nuclear Factor-κappa B (NF-κB) is a family of critical transcription factors of the inflammatory pathway and plays an imperative role in the progression of various cancers such as breast, lung, liver, pancreatic, prostate and multiple types of lymphoma. NF- κB develops an inherent relationship between inflammation and cancer. It is a crucial factor that controls the ability of malignant and pre-neoplastic cells to prevent programmed cell death-based tumor-surveillance channels. Due to its high significance in the onset and progression of various cancers, it has become an excellent target for cancer therapy. The emerging targeted therapies provide a lot of hope, whereby a single protein or generally the target enzyme is completely blocked. Several natural compounds have shown anticancer and anti-inflammatory activities by inhibiting the NF-κB pathway in various cancer types. About 750 natural and synthetic inhibitors of the NF-κB have been reported. These inhibitors include microbial and viral proteins, small RNA/DNA, antioxidants, small molecules, peptides, and engineered constitutively active polypeptides, all of which may inhibit canonical and alternative NF-κB pathways. Thus, blocking or targeting the NF-κB-signaling pathways using natural and synthetic compounds could be a potential mechanism to cure the NF-κB induced tumors.